



**May 28, 2009**

**CONTACT:  
Alison Worley  
919-595-0321**

**IBC MEETING, 2009**

**Research Triangle Park** – AlphaVax, Inc. will hold its annual Institutional Biosafety Committee (IBC) Meeting on Friday, June 12<sup>th</sup>, 2009, at 12 noon.

The meeting, which is open to the public, will be held at AlphaVax, Inc.'s corporate offices located at 2 Triangle Drive, Research Triangle Park, NC 27709.

If you wish to attend, or would like further information, please contact Alison Worley.

**About AlphaVax**

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. AlphaVax is developing vaccine products for herpes simplex virus, influenza, respiratory syncytial virus, HIV and a number of biodefense targets. In addition, AlphaVax is developing this novel product platform for cancer immunotherapy. A phase I/II clinical trial for a CEA tumor vaccine is currently ongoing at Duke University and a Her2 breast cancer clinical trial is planned for later this year. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Lenoir, NC. The company employs staff with expertise spanning vaccine design, process development, GMP manufacturing, quality assurance, and regulatory and clinical affairs. [www.alphavax.com](http://www.alphavax.com)

###